At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 635 enrolled
Drug / intervention
Iloperidone +1 moredrug
Likely dose
Iloperidone 12 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate Prevention of Relapse in Patients With Schizophrenia Receiving Either Flexible Dose Iloperidone or Placebo in Long-term Use (up to 26 Weeks) Followed by up to 52 Weeks of Open-label Extension
In Brief
A Phase 3 clinical trial evaluating Iloperidone and Placebo for Schizophrenia. Completed, enrolled 635 participants across 63 sites in 3 countries.
Detailed Summary
The purpose of this study is to determine whether Iloperidone is effective in the prevention of relapse in patients with schizophrenia
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSchizophrenia
CountriesIndia, Ukraine, United States
Collaborators--
Timeline
Phase 3CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartFeb 2011
First PostedFeb 2011
Primary CompletionMar 2014
Study CompletionMar 2015
TodayJul 2026
First PostedFeb 8, 2011
Enrollment StartFeb 1, 2011
Primary CompletionMar 1, 2014
Study CompletionMar 1, 2015
TodayJul 2, 2026
Enrollment to primary: 3.1 yearsPosted 15.4 years ago
Interventions
Iloperidonedrug
Over-encapsulated iloperidone tablets were administered orally using a bid schedule; the strengths used include 1, 2, 4, 6, 8, 10, and 12 mg.
Placebodrug
Matching placebo capsules were administered orally using a bid schedule during the double-blind period.